ISRCTN12682719
Active, not recruiting
未知
Antidepressant for the prevention of DEPression following first-episode Psychosis: the ADEPP trial
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Psychosis
- Sponsor
- niversity of Birmingham
- Enrollment
- 452
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37803384/ (added 10/10/2023)
Investigators
Eligibility Criteria
Inclusion Criteria
- •Current inclusion criteria as of 20/03/2023:
- •1\. Diagnosis of first\-episode psychosis (FEP)
- •2\. Within 12 months of initial treatment for FEP (as defined by onset of care provision by an Early Intervention Team)
- •3\. Positive and Negative Syndrome Scale (PANSS) individual positive item scores all \=4
- •4\. Sufficiently recovered from acute psychotic episode with capacity to consent
- •5\. Males and females aged 18\-65 years
- •6\. Currently prescribed antipsychotic medication at stable dose.
- •7\. Female participants must be willing to use one form of highly effective contraception
- •Previous inclusion criteria:
- •1\. Diagnosis of first\-episode psychosis (FEP)
Exclusion Criteria
- •Current exclusion criteria as of 20/03/2023:
- •1\. Current moderate or severe depression (as indicated by a Calgary Depression for Schizophrenia Scale (CDSS) score of \> 7\)
- •2\. Currently prescribed antidepressant medication (or within 2 weeks of stopping if a Monoamine Oxidase Inhibitor)
- •3\. Previous history of mania
- •4\. Contraindications to selective serotonin reuptake inhibitors (SSRI) antidepressant treatment (e.g. recurrent thrombotic illness, previous adverse reaction, confirmed pregnancy, although risk in pregnancy is low, prescribed pimozide)
- •5\. Serious medical or neurological illness (as identified by the treating consultant psychiatrist)
- •6\. Hypersensitivity to the active substance or any of the excipients or placebo
- •7\. Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs)
- •8\. Patient with any other systemic dysfunction (e.g. gastrointestinal, renal, respiratory, cardiovascular, neurological or psychiatric) or significant disorder which, in the opinion of the investigator would jeopardize the safety of the patient by taking part in the trial
- •9\. Electrocardiogram (ECG): QTc interval \>450 as measured in the last 12 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
IDEA: Intervention to prevent depressive symptoms and promote well-being in early stage dementiaISRCTN75503960niversity College London63
Completed
Not Applicable
Preventing depression study: PERSUADEISRCTN23278208The University of Manchester64
Completed
Not Applicable
Targeting repetitive intrusive suicidal images and thoughts: towards a new suicide prevention strategy (Simagery)Suicidal intrusions in psychiatric outpatients with elevated levels of depression and suicidal ideationMental and Behavioural DisordersISRCTN17404612VU Amsterdam91
Completed
Not Applicable
Trial of Internet and telephone support to people coming off long-term antidepressantsMood [affective] disordersMental and Behavioural DisordersISRCTN12417565niversity of Southampton330
Completed
Not Applicable
Integrating depression management in HIV care in UgandaISRCTN86760765MRC/UVRI Uganda Research Unit on AIDS800